romosozumab HCP administration with PFS
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Menopausal Osteoporosis
Conditions
Post-Menopausal Osteoporosis
Trial Timeline
Feb 6, 2018 → Jan 8, 2020
NCT ID
NCT03432533About romosozumab HCP administration with PFS
romosozumab HCP administration with PFS is a phase 3 stage product being developed by Amgen for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03432533. Target conditions include Post-Menopausal Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03432533 | Phase 3 | Completed |
Competing Products
19 competing products in Post-Menopausal Osteoporosis